Published in J Biol Chem on July 10, 2012
Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes. Nucleic Acids Res (2012) 1.60
Analysis of an artificial zinc finger epigenetic modulator: widespread binding but limited regulation. Nucleic Acids Res (2014) 0.95
Epigenome engineering in cancer: fairytale or a realistic path to the clinic? Front Oncol (2015) 0.92
Enabling functional genomics with genome engineering. Genome Res (2015) 0.90
Stable oncogenic silencing in vivo by programmable and targeted de novo DNA methylation in breast cancer. Oncogene (2015) 0.89
Writing and rewriting the epigenetic code of cancer cells: from engineered proteins to small molecules. Mol Pharmacol (2012) 0.88
Breaking through an epigenetic wall: re-activation of Oct4 by KRAB-containing designer zinc finger transcription factors. Epigenetics (2013) 0.85
Can genome engineering be used to target cancer-associated enhancers? Epigenomics (2014) 0.81
Prolonged re-expression of the hypermethylated gene EPB41L3 using artificial transcription factors and epigenetic drugs. Epigenetics (2015) 0.80
Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system. Oncotarget (2016) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Identifying biological themes within lists of genes with EASE. Genome Biol (2003) 31.72
Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 A. Science (1991) 15.97
Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell (2010) 14.18
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol (2005) 6.22
Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. Proc Natl Acad Sci U S A (1998) 5.46
Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science (1994) 5.37
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet (2001) 5.08
Role for DNA methylation in the control of cell type specific maspin expression. Nat Genet (2002) 4.72
Engineering polydactyl zinc-finger transcription factors. Nat Biotechnol (2002) 4.40
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res (2008) 3.98
Positive and negative regulation of endogenous genes by designed transcription factors. Proc Natl Acad Sci U S A (2000) 3.92
Cloning and functional characterization of novel large conductance calcium-activated potassium channel beta subunits, hKCNMB3 and hKCNMB4. J Biol Chem (2000) 3.75
Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells. Nucleic Acids Res (2005) 3.47
Regulation of an endogenous locus using a panel of designed zinc finger proteins targeted to accessible chromatin regions. Activation of vascular endothelial growth factor A. J Biol Chem (2001) 3.38
Development of zinc finger domains for recognition of the 5'-ANN-3' family of DNA sequences and their use in the construction of artificial transcription factors. J Biol Chem (2001) 3.35
Design of polydactyl zinc-finger proteins for unique addressing within complex genomes. Proc Natl Acad Sci U S A (1997) 2.97
Building zinc fingers by selection: toward a therapeutic application. Proc Natl Acad Sci U S A (1995) 2.92
Synthetic zinc finger transcription factor action at an endogenous chromosomal site. Activation of the human erythropoietin gene. J Biol Chem (2000) 2.85
Scanning the human genome with combinatorial transcription factor libraries. Nat Biotechnol (2003) 2.75
Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer (2004) 2.31
New advances in ovarian cancer. Oncology (Williston Park) (2010) 2.27
Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci U S A (1996) 2.20
Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci U S A (2011) 2.01
TALE nucleases: tailored genome engineering made easy. Curr Opin Biotechnol (2012) 1.96
VP16-dependent association of chromatin-modifying coactivators and underrepresentation of histones at immediate-early gene promoters during herpes simplex virus infection. J Virol (2004) 1.89
Maspin regulates different signaling pathways for motility and adhesion in aggressive breast cancer cells. Cancer Biol Ther (2003) 1.85
The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res (2002) 1.71
Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. J Exp Med (1993) 1.70
Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2003) 1.49
Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. Am J Pathol (1998) 1.46
Identification of suitable reference genes for gene expression studies of human serous ovarian cancer by real-time polymerase chain reaction. Anal Biochem (2009) 1.44
Essential role of CIB1 in regulating PAK1 activation and cell migration. J Cell Biol (2005) 1.38
Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene (2006) 1.35
maspin suppresses the invasive phenotype of human breast carcinoma. Cancer Res (1998) 1.32
Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter. Nucleic Acids Res (2000) 1.28
Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. Gynecol Oncol (2006) 1.26
Maspin expression in invasive breast cancer: association with other prognostic factors. J Pathol (2003) 1.25
Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor. Breast Cancer Res (2011) 1.24
Expression of the CCAAT/enhancer-binding proteins C/EBPalpha, C/EBPbeta and C/EBPdelta in breast cancer: correlations with clinicopathologic parameters and cell-cycle regulatory proteins. Breast Cancer Res Treat (2003) 1.19
Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. Mol Cancer Ther (2008) 1.16
Advances in the management of epithelial ovarian cancer. J Reprod Med (2005) 1.13
Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation. Clin Cancer Res (2002) 1.13
Tetraspanin protein contributions to cancer. Biochem Soc Trans (2011) 1.12
Ovarian cancer: pathology, biology, and disease models. Front Biosci (Landmark Ed) (2009) 1.11
Immunohistochemically detected expression of motility-related protein-1 (MRP-1/CD9) in lung adenocarcinoma and its relation to prognosis. Int J Cancer (1997) 1.10
Genetic reprogramming of tumor cells by zinc finger transcription factors. Proc Natl Acad Sci U S A (2005) 1.07
Nuclear localization of maspin is essential for its inhibition of tumor growth and metastasis. Lab Invest (2011) 1.07
Development of a syngeneic mouse model of epithelial ovarian cancer. J Ovarian Res (2010) 1.06
MRP-1/CD9 gene transduction downregulates Wnt signal pathways. Oncogene (2004) 1.05
C/EBP-δ regulates VEGF-C autocrine signaling in lymphangiogenesis and metastasis of lung cancer through HIF-1α. Oncogene (2011) 1.05
Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer (2005) 1.05
Identification of genes for normalization of quantitative real-time PCR data in ovarian tissues. Acta Biochim Biophys Sin (Shanghai) (2010) 1.03
The expression and functional characterization of sigma (sigma) 1 receptors in breast cancer cell lines. Cancer Lett (2006) 1.02
Epigenetic regulation of maspin expression in human ovarian carcinoma cells. Gynecol Oncol (2006) 1.01
Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics. Clin Cancer Res (2008) 1.00
Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs). Epigenetics (2011) 1.00
Down-regulation of CD9 in human ovarian carcinoma cell might contribute to peritoneal dissemination: morphologic alteration and reduced expression of beta1 integrin subsets. Cancer Res (2005) 0.99
Tetraspanins and tumor progression. Clin Exp Metastasis (2010) 0.98
Animal models of ovarian cancer. Cancer Treat Res (2009) 0.98
Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity. BMC Cancer (2008) 0.94
Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1. Mol Cancer (2008) 0.93
Development and characterization of a progressive series of mammary adenocarcinoma cell lines derived from the C3(1)/SV40 Large T-antigen transgenic mouse model. Breast Cancer Res Treat (2003) 0.92
Suppression of breast tumor growth and metastasis by an engineered transcription factor. PLoS One (2011) 0.91
Interrogating genomes with combinatorial artificial transcription factor libraries: asking zinc finger questions. Assay Drug Dev Technol (2006) 0.89
Current and future directions of clinical trials for ovarian cancer. Cancer Control (2011) 0.89
Circadian disruption accelerates tumor growth and angio/stromagenesis through a Wnt signaling pathway. PLoS One (2010) 0.89
The natural tumor suppressor protein maspin and potential application in non small cell lung cancer. Curr Pharm Des (2010) 0.88
Nidogen-1 and nidogen-2 are found in basement membranes during human embryonic development. Histochem J (2002) 0.88
Rational design, selection and specificity of artificial transcription factors (ATFs): the influence of chromatin in target gene regulation. Comb Chem High Throughput Screen (2008) 0.87
Cyclophilin a protects Peg3 from hypermethylation and inactive histone modification. J Biol Chem (2006) 0.87
Remodeling genomes with artificial transcription factors (ATFs). Methods Mol Biol (2010) 0.83
Nuclear maspin expression as a good prognostic factor in human epithelial ovarian carcinoma. Folia Morphol (Warsz) (2010) 0.81
Identification of DNA-binding of tumor suppressor genes by chromatin immunoprecipitation. Methods Mol Biol (2003) 0.78
Investigating maspin in breast cancer progression using mouse models. Methods Enzymol (2011) 0.76
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med (2007) 5.39
Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm (2008) 3.92
Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One (2010) 3.38
Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther (2007) 3.03
Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther (2010) 2.78
Development of zinc finger domains for recognition of the 5'-CNN-3' family DNA sequences and their use in the construction of artificial transcription factors. J Biol Chem (2005) 2.69
Focus on epithelial ovarian cancer. Cancer Cell (2004) 2.47
Evaluation of a modular strategy for the construction of novel polydactyl zinc finger DNA-binding proteins. Biochemistry (2003) 2.33
Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer (2004) 2.31
Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther (2010) 2.30
Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev (2009) 2.28
Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm (2006) 2.28
An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Release (2008) 1.95
Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta (2009) 1.94
Targeted nanoparticles deliver siRNA to melanoma. J Invest Dermatol (2010) 1.81
Elevated CO2 induces physiological, biochemical and structural changes in leaves of Arabidopsis thaliana. New Phytol (2006) 1.80
RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res (2007) 1.76
Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release (2009) 1.76
Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther (2008) 1.74
Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J Control Release (2011) 1.72
Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J Control Release (2007) 1.68
Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics (2012) 1.65
Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release (2010) 1.64
In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol Ther (2012) 1.59
Non-viral is superior to viral gene delivery. J Control Release (2007) 1.54
Activation of hypothalamic S6 kinase mediates diet-induced hepatic insulin resistance in rats. J Clin Invest (2008) 1.53
NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res (2009) 1.53
Nonviral methods for siRNA delivery. Mol Pharm (2009) 1.50
Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PLoS One (2013) 1.48
Recent advances in nonviral vectors for gene delivery. Acc Chem Res (2011) 1.48
Surface-modified LPD nanoparticles for tumor targeting. Ann N Y Acad Sci (2006) 1.46
Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Res (2012) 1.40
Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res (2010) 1.38
Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst (2002) 1.35
Breastmilk is a novel source of stem cells with multilineage differentiation potential. Stem Cells (2012) 1.31
Strategies for high-resolution imaging of epithelial ovarian cancer by laparoscopic nonlinear microscopy. Transl Oncol (2010) 1.31
Nanostructured calcium phosphates (NanoCaPs) for non-viral gene delivery: influence of the synthesis parameters on transfection efficiency. Biomaterials (2006) 1.30
Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem (2010) 1.28
Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. J Am Chem Soc (2010) 1.27
Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor. Breast Cancer Res (2011) 1.24
Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol Immunol (2007) 1.24
Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res (2006) 1.22
A highly efficient synthetic vector: nonhydrodynamic delivery of DNA to hepatocyte nuclei in vivo. ACS Nano (2013) 1.22
Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine (2012) 1.21
Development of non-viral vectors for systemic gene delivery. J Control Release (2002) 1.21
Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Mol Pharm (2009) 1.21
Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats. J Pharmacol Exp Ther (2005) 1.19
Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol Ther (2010) 1.17
The type of dietary fat modulates intestinal tight junction integrity, gut permeability, and hepatic toll-like receptor expression in a mouse model of alcoholic liver disease. Alcohol Clin Exp Res (2011) 1.17
Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. Mol Cancer Ther (2008) 1.16
Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer. Cancer Biol Ther (2007) 1.15
Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. Mol Ther (2011) 1.15
Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol Ther (2013) 1.12
Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. Mol Pharm (2005) 1.11
Targeted cancer therapy with novel high drug-loading nanocrystals. J Pharm Sci (2010) 1.10
Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev (2005) 1.10
MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastoma. Cancer Res (2011) 1.09
Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53. PLoS One (2009) 1.09
The suppressive tumor microenvironment: a challenge in cancer immunotherapy. Mol Pharm (2011) 1.08
A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol Immunother (2007) 1.08
Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. J Control Release (2013) 1.08
HIV-1 Tat protein transduction domain peptide facilitates gene transfer in combination with cationic liposomes. J Control Release (2004) 1.08
Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther (2012) 1.07
Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. ACS Nano (2013) 1.07
Development of a syngeneic mouse model of epithelial ovarian cancer. J Ovarian Res (2010) 1.06
Disruption of actin filaments by latrunculin B affects cell wall construction in Picea meyeri pollen tube by disturbing vesicle trafficking. Plant Cell Physiol (2006) 1.05
Bile acids increase response and expression of human myometrial oxytocin receptor. Am J Obstet Gynecol (2003) 1.04
LPD nanoparticles--novel nonviral vector for efficient gene delivery. Methods Mol Med (2002) 1.03
Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine. J Control Release (2008) 1.03
Paclitaxel nanocrystals for overcoming multidrug resistance in cancer. Mol Pharm (2010) 1.02
Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo. Clin Cancer Res (2006) 1.02
In vivo selection of combinatorial libraries and designed affinity maturation of polydactyl zinc finger transcription factors for ICAM-1 provides new insights into gene regulation. J Mol Biol (2004) 1.02
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci U S A (2006) 1.02
Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia (2012) 1.02
Role of transcription factor NFAT in glucose and insulin homeostasis. Mol Cell Biol (2006) 1.02
Mechanistic studies of sequential injection of cationic liposome and plasmid DNA. Mol Ther (2005) 1.01
Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. Cancer Immunol Immunother (2005) 1.01
Biodistribution studies of nanoparticles using fluorescence imaging: a qualitative or quantitative method? Pharm Res (2012) 1.00
Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs). Epigenetics (2011) 1.00
Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer. Mol Pharm (2012) 1.00
Biosynthesis and characterization of a novel genetically engineered polymer for targeted gene transfer to cancer cells. J Control Release (2009) 1.00
Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. Biomaterials (2013) 0.99
Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol Ther (2013) 0.98
Promoter-targeted phage display selections with preassembled synthetic zinc finger libraries for endogenous gene regulation. J Mol Biol (2004) 0.98
Electroporatic delivery of TGF-beta1 gene works synergistically with electric therapy to enhance diabetic wound healing in db/db mice. J Invest Dermatol (2004) 0.98